Related Experiment Video
Updated: Jun 11, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA,
1Department of Physiology, Royal College of Surgeons in Ireland, Ireland. docherty@rcsi.ie
Abstract:
Hyperthermia is probably the most widely known acute adverse event that can follow ingestion of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) by recreational users. The effect of MDMA on body temperature is complex because the drug has actions on all three major monoamine neurotransmitters [5-hydroxytryptamine (5-HT), dopamine and noradrenaline], both by amine release and by direct receptor activation. Hyperthermia and hypothermia can be induced in laboratory animals by MDMA, depending on the ambient temperature, and involve both central thermoregulation and peripheral changes in blood flow and thermogenesis. Acute 5-HT release is not directly responsible for hyperthermia, but 5-HT receptors are involved in modulating the hyperthermic response. Impairing 5-HT function with a neurotoxic dose of MDMA or p-chlorophenylalanine alters the subsequent MDMA-induced hyperthermic response. MDMA also releases dopamine, and evidence suggests that this transmitter is involved in both the hyperthermic and hypothermic effects of MDMA in rats. The noradrenergic system is also involved in the hyperthermic response to MDMA. MDMA activates central alpha(2A)-adrenoceptors and peripheral alpha(1)-adrenoceptors to produce cutaneous vasoconstriction to restrict heat loss, and beta(3)-adrenoceptors in brown adipose tissue to increase heat generation. The hyperthermia occurring in recreational users of MDMA can be fatal, but data reviewed here indicate that it is unlikely that any single pharmaceutical agent will be effective in reversing the hyperthermia, so careful body cooling remains the principal clinical approach. Crucially, educating recreational users about the potential dangers of hyperthermia and the control of ambient temperature should remain key approaches to prevent this potentially fatal problem.
Insights
3,4-methylenedioxymethamphetamine (MDMA, ecstasy) can cause fatal hyperthermia by affecting multiple neurotransmitters. While cooling is the primary treatment, educating users on risks and temperature control is crucial for prevention.
Area of Science:
- Neuroscience
- Pharmacology
- Toxicology
Background:
- Hyperthermia is a dangerous acute adverse event associated with recreational 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) use.
- MDMA's complex effects on body temperature stem from its actions on serotonin, dopamine, and noradrenaline neurotransmitter systems.
- Both hyperthermia and hypothermia can be induced by MDMA in animals, involving central thermoregulation and peripheral physiological changes.
Purpose of the Study:
- To review the mechanisms underlying MDMA-induced hyperthermia.
- To explore the roles of different neurotransmitter systems in MDMA's thermoregulatory effects.
- To discuss clinical approaches and preventative strategies for MDMA-induced hyperthermia.
Main Methods:
- Review of existing scientific literature on MDMA's effects on body temperature.
- Analysis of studies investigating the involvement of 5-HT, dopamine, and noradrenaline pathways.
- Examination of animal models and human recreational use data.
Main Results:
- Acute serotonin release is not directly responsible for hyperthermia, but serotonin receptors modulate the response.
- Dopamine appears involved in both hyperthermic and hypothermic effects.
- Noradrenergic system activation leads to heat loss restriction (vasoconstriction) and increased heat generation (thermogenesis).
Conclusions:
- MDMA-induced hyperthermia can be fatal, with limited pharmaceutical reversal options.
- Body cooling is the primary clinical intervention for hyperthermia.
- Education on MDMA risks and ambient temperature control are key preventative measures.
More Related Videos
Related Concept Videos
CNS Stimulants: Psychedelic Agents
Thermoregulation
Toxidromes: Clinical Features
Increased Body Temperature
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Drugs Affecting Neurotransmitter Release or Uptake

